Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Current Leases (2021 - 2025)

Crinetics Pharmaceuticals has reported Current Leases over the past 5 years, most recently at $6.5 million for Q4 2025.

  • For Q4 2025, Current Leases fell 9.27% year-over-year to $6.5 million; the TTM value through Dec 2025 reached $6.5 million, down 9.27%, while the annual FY2025 figure was $6.5 million, 9.27% down from the prior year.
  • Current Leases for Q4 2025 was $6.5 million at Crinetics Pharmaceuticals, up from $6.4 million in the prior quarter.
  • Over five years, Current Leases peaked at $7.4 million in Q2 2024 and troughed at $939000.0 in Q4 2021.
  • A 5-year average of $4.5 million and a median of $5.8 million in 2024 define the central range for Current Leases.
  • Biggest five-year swings in Current Leases: surged 571.33% in 2024 and later decreased 13.11% in 2025.
  • Year by year, Current Leases stood at $939000.0 in 2021, then rose by 11.93% to $1.1 million in 2022, then skyrocketed by 297.05% to $4.2 million in 2023, then soared by 71.39% to $7.2 million in 2024, then decreased by 9.27% to $6.5 million in 2025.
  • Business Quant data shows Current Leases for CRNX at $6.5 million in Q4 2025, $6.4 million in Q3 2025, and $6.6 million in Q2 2025.